AIM: To explore the feasibility of local interleukin 2 (IL-2) in patients with different forms of abdominal cancer. This required experimentation with the time interval between IL-2 applications and the methods of application. METHODS: Sixteen patients with stages III and IV of gastrointestinal malignancies (primary or metastatic) who were admitted to our Department of Gastroenterology were treated with locoregionally applied IL-2 in low doses. RESULTS: No major problems applying locoregional IL-2 were encountered. In 6 out of 16 patients, a modest but clinically worthwhile improvement was obtained. Adverse effects were minimal. The therapeutic scheme was well tolerated, even in patients in a poor condition. CONCLUSION: This study demonstrates the feasibility of low dose locoregional IL-2 application in advanced abdominal cancer. Local IL-2 therapy gives only negligible adverse effects. The results suggest that it is important to apply intratumorally. Local IL-2 may be given adjunct to standard therapeutic regimes and does not imply complex surgical interventions. These initial results are encouraging.
AIM: To explore the feasibility of local interleukin 2 (IL-2) in patients with different forms of abdominal cancer. This required experimentation with the time interval between IL-2 applications and the methods of application. METHODS: Sixteen patients with stages III and IV of gastrointestinal malignancies (primary or metastatic) who were admitted to our Department of Gastroenterology were treated with locoregionally applied IL-2 in low doses. RESULTS: No major problems applying locoregional IL-2 were encountered. In 6 out of 16 patients, a modest but clinically worthwhile improvement was obtained. Adverse effects were minimal. The therapeutic scheme was well tolerated, even in patients in a poor condition. CONCLUSION: This study demonstrates the feasibility of low dose locoregional IL-2 application in advanced abdominal cancer. Local IL-2 therapy gives only negligible adverse effects. The results suggest that it is important to apply intratumorally. Local IL-2 may be given adjunct to standard therapeutic regimes and does not imply complex surgical interventions. These initial results are encouraging.
Authors: L A Everse; I B Renes; I M Jürgenliemk-Schulz; D H Rutgers; M R Bernsen; H F Dullens; W Den Otter; J J Battermann Journal: Int J Cancer Date: 1997-09-17 Impact factor: 7.396
Authors: John J L Jacobs; Gerrit J Hordijk; Ina M Jürgenliemk-Schulz; Chris H J Terhaard; Jan W Koten; Jan J Battermann; Willem Den Otter Journal: Cancer Immunol Immunother Date: 2004-12-31 Impact factor: 6.968
Authors: M R Bernsen; A W Van Der Velden; L A Everse; H F Dullens; W Den Otter; A P Heintz Journal: Cancer Immunol Immunother Date: 1998-03 Impact factor: 6.968
Authors: W Den Otter; F W Hill; W R Klein; J W Koten; P A Steerenberg; P H De Mulder; C Rhode; R Stewart; J A Faber; E J Ruitenberg Journal: Cancer Immunol Immunother Date: 1995-07 Impact factor: 6.968
Authors: L T Balemans; P A Steerenberg; F J Koppenhagen; B H Kremer; P H De Mulder; A M Claessen; R J Scheper; W Den Otter Journal: Int J Cancer Date: 1994-09-15 Impact factor: 7.396
Authors: L T Balemans; V Mattijssen; P A Steerenberg; B E Van Driel; P H De Mulder; W Den Otter Journal: Cancer Immunol Immunother Date: 1993-07 Impact factor: 6.968
Authors: Annika N Haagsman; Astrid C S Witkamp; Bart E Sjollema; Marja J L Kik; Jolle Kirpensteijn Journal: BMC Vet Res Date: 2013-08-08 Impact factor: 2.741
Authors: Willem Den Otter; John J L Jacobs; Jan J Battermann; Gerrit Jan Hordijk; Zachary Krastev; Ekaterina V Moiseeva; Rachel J E Stewart; Paul G P M Ziekman; Jan Willem Koten Journal: Cancer Immunol Immunother Date: 2008-07 Impact factor: 6.968